Clinical and Genetic Findings in Patients With PRPF31-associated Retinitis Pigmentosa
1 other identifier
observational
87
1 country
1
Brief Summary
Retrospective chart review study to elucidate the genotype and phenotype of patients with PRPF31-associated retinitis pigmentosa and asymptomatic carriers of the respective variant(s)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2023
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2023
CompletedFirst Submitted
Initial submission to the registry
April 4, 2024
CompletedFirst Posted
Study publicly available on registry
April 16, 2024
CompletedApril 16, 2024
March 1, 2024
6 months
April 4, 2024
April 10, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (7)
Best Corrected Visual Acuity (BCVA)
best corrected visual acuity
September 2007 - January 2022
Visual Field (VF)
visual field as measured by semi-automated 90° kinetic visual field exam using target III4e
September 2007 - January 2022
Fundus Photography (FP)
characterization of the retina with fundus photography
September 2007 - January 2022
Optos
characterization of the retina with ultra-wide-field scanning laser ophthalmoscopy
September 2007 - January 2022
Autofluorescence (AF)
characterization of the retina with fundus autofluorescence
September 2007 - January 2022
Optical Coherence Tomography (OCT)
characterization of the retina with optical coherence tomography, e.g. foveal ellipsoid zone loss
September 2007 - January 2022
Full-Field Electroretinogram (ff-ERG)
characterization of retinal function with full-field electroretinogram
September 2007 - January 2022
Eligibility Criteria
Patients with genetically confirmed PRPF31-associated inherited retinal dystrophy or asymptomatic carrier of the respective variant(s)
You may qualify if:
- genetically confirmed PRPF31-associated inherited retinal dystrophy or asymptomatic carrier of the respective variant(s)
You may not qualify if:
- none
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Hospital Tuebingen
Tübingen, Baden-Wurttemberg, 72076, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Laura Kuehlewein, MD
Department for Ophthalmology, University of Tuebingen
- PRINCIPAL INVESTIGATOR
Susanne Kohl, PhD
Molecular Genetics Laboratory, Department for Ophthalmology, University of Tuebingen
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 4, 2024
First Posted
April 16, 2024
Study Start
January 1, 2023
Primary Completion
June 30, 2023
Study Completion
June 30, 2023
Last Updated
April 16, 2024
Record last verified: 2024-03
Data Sharing
- IPD Sharing
- Will not share